Synthetic Lethality between DNA Polymerase Epsilon and RTEL1 in Metazoan DNA Replication.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
26 05 2020
Historique:
received: 20 02 2020
revised: 28 03 2020
accepted: 30 04 2020
entrez: 28 5 2020
pubmed: 28 5 2020
medline: 22 5 2021
Statut: ppublish

Résumé

Genome stability requires coordination of DNA replication origin activation and replication fork progression. RTEL1 is a regulator of homologous recombination (HR) implicated in meiotic cross-over control and DNA repair in C. elegans. Through a genome-wide synthetic lethal screen, we uncovered an essential genetic interaction between RTEL1 and DNA polymerase (Pol) epsilon. Loss of POLE4, an accessory subunit of Pol epsilon, has no overt phenotype in worms. In contrast, the combined loss of POLE-4 and RTEL-1 results in embryonic lethality, accumulation of HR intermediates, genome instability, and cessation of DNA replication. Similarly, loss of Rtel1 in Pole4

Identifiants

pubmed: 32460026
pii: S2211-1247(20)30628-8
doi: 10.1016/j.celrep.2020.107675
pmc: PMC7262601
pii:
doi:

Substances chimiques

DNA Polymerase II EC 2.7.7.7
RTEL1 protein, human EC 3.6.1.-
DNA Helicases EC 3.6.4.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

107675

Subventions

Organisme : Cancer Research UK
ID : FC0010048
Pays : United Kingdom
Organisme : Medical Research Council
ID : FC0010048
Pays : United Kingdom
Organisme : Wellcome Trust
ID : FC0010048
Pays : United Kingdom

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests S.J.B. is scientific co-founder and SVP Science Strategy at Artios Pharma Ltd., Babraham, UK.

Références

Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):8956-61
pubmed: 18579778
Open Biol. 2019 Sep 27;9(9):190156
pubmed: 31506018
Mol Cell. 2018 May 17;70(4):707-721.e7
pubmed: 29754823
Mol Cell. 2015 Feb 19;57(4):622-635
pubmed: 25620558
Cell. 2008 Oct 17;135(2):261-71
pubmed: 18957201
Genes Dev. 2007 Dec 15;21(24):3331-41
pubmed: 18079179
Nature. 2003 Jan 16;421(6920):231-7
pubmed: 12529635
Nat Rev Genet. 2017 Sep;18(9):535-550
pubmed: 28714480
Cell. 2012 May 11;149(4):795-806
pubmed: 22579284
Science. 2013 Oct 11;342(6155):239-42
pubmed: 24115439
DNA Repair (Amst). 2014 Jul;19:152-62
pubmed: 24815912
Science. 2010 Mar 5;327(5970):1254-8
pubmed: 20203049
Nat Rev Mol Cell Biol. 2014 Jan;15(1):7-18
pubmed: 24326623
Nat Rev Mol Cell Biol. 2017 May;18(5):315-330
pubmed: 28327556
EMBO J. 2007 Jul 25;26(14):3384-96
pubmed: 17611606
Mol Cell Biol. 2004 Jun;24(11):5016-27
pubmed: 15143192
Annu Rev Biochem. 2017 Jun 20;86:417-438
pubmed: 28301743
Genetics. 2006 Jun;173(2):697-708
pubmed: 16547095
Cell. 2019 Jan 10;176(1-2):167-181.e21
pubmed: 30595447
Genetics. 2016 Jul;203(3):1027-67
pubmed: 27384026
Mol Cell. 2015 Sep 17;59(6):998-1010
pubmed: 26365379
PLoS Genet. 2009 Nov;5(11):e1000735
pubmed: 19936019
Nat Struct Mol Biol. 2018 Jun;25(6):446-453
pubmed: 29807999
Cell. 1995 Jan 13;80(1):29-39
pubmed: 7813016
Nat Rev Mol Cell Biol. 2015 Jun;16(6):360-74
pubmed: 25999062
Mol Cell Biol. 2008 Mar;28(5):1470-9
pubmed: 18086896
Nat Cell Biol. 2014 Jan;16(1):2-9
pubmed: 24366029
Nat Genet. 2002 Aug;31(4):405-9
pubmed: 12101400
Genes Dev. 2010 Mar 15;24(6):602-12
pubmed: 20231317

Auteurs

Roberto Bellelli (R)

The Francis Crick Institute, 1 Midland Road, NW1 1AT London, UK.

Jillian Youds (J)

The Francis Crick Institute, 1 Midland Road, NW1 1AT London, UK.

Valerie Borel (V)

The Francis Crick Institute, 1 Midland Road, NW1 1AT London, UK.

Jennifer Svendsen (J)

The Francis Crick Institute, 1 Midland Road, NW1 1AT London, UK.

Visnja Pavicic-Kaltenbrunner (V)

The Francis Crick Institute, 1 Midland Road, NW1 1AT London, UK.

Simon J Boulton (SJ)

The Francis Crick Institute, 1 Midland Road, NW1 1AT London, UK. Electronic address: simon.boulton@crick.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH